NEW YORK (GenomeWeb News) – Precision BioSciences said today that it is suing Lonza Group and a number of its affiliates for patent infringement.

The lawsuit, filed in the US District Court for the District of Delaware, alleges that Switzerland-based Lonza's import and sale of its GS Xceed Gene Expression System and CHOK1SV knock-out cell line in the US infringes US Patent No. 8,377,674, which applies to Precision Bio's Directed Nuclease Editor genome editing technology.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: researchers classify pancreatic cancer into four subtypes using sequencing, and more.

Genotyping analysis of measles in Ontario indicates the strain there didn't originate from Disneyland or Europe.

The UK Medical Research Council says the proposed path of a new train line could affect research at the Francis Crick Institute.

The House of Lords in the UK approves a bill to allow mitochondrial donation.